A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg assay panel and the B-Cell/antibody response panel to predict the clinical effect of Octagam® 5% in subjects with relapsing/remitting multiple sclerosis
ISRCTN | ISRCTN57377482 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN57377482 |
Secondary identifying numbers | GAM-25 |
- Submission date
- 18/03/2009
- Registration date
- 18/03/2009
- Last edited
- 10/04/2013
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Stefan Wietek
Scientific
Scientific
Octapharma PPG
Vienna CR&D Office
Oberlaaer Str. 235
Vienna
1100
Austria
Phone | +43 (0)1 61032 1778 |
---|---|
stefan.wietek@octapharma.com |
Study information
Study design | Prospective exploratory open label multicentre phase II trial |
---|---|
Primary study design | Interventional |
Secondary study design | Non randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | |
Study objectives | To find a panel of laboratory parameters which might be able to predict the clinical outcome of treatment of patients with relapsing-remitting multiple sclerosis (MS) with Octagam®. |
Ethics approval(s) | 1. EC Medical University of Innsbruck (Austria) - includes approval for Linz and Klagenfurt; approval received on the 9th January 2009 and final approval for additional study materials received on 22nd January 2009 2. EC Heidelberg (Germany) - includes approval for study sites at Heidelberg, Asbach, Berlin, Hamburg, Regensburg, Rostock; approval received on the 31st March 2009 |
Health condition(s) or problem(s) studied | Multiple sclerosis |
Intervention | Octagam® 5% (12 infusions 0.4 g/kg every 4 weeks). |
Intervention type | Other |
Primary outcome measure | A panel of lab parameters (components of cells of the immune system, serum proteins, gene expression, single nucleotide polymorphism [SNP] analysis) will be analysed at baseline, 12 - 24 hours after end of the first infusion, and 24 and 48 weeks after the first Octagam® administration and the clinical course of the disease will be monitored by relapse activity, EDSS and Multiple Sclerosis Functional Composite (MSFC) at predefined time points. Statistical analysis will test whether any of the lab parameters of the HAP panel or the B-cell antibody response panel might be able to predict the clinical outcome observed following Octagam® 5% treatment. The proportion of subjects clinically responding to Octagam® 5% will be determined. |
Secondary outcome measures | Lesion load in brain MRI imaging (T2 weighted, T1 weighted, Gd-enhancing lesion load) after treatment will be compared to lesion load before treatment. |
Overall study start date | 20/03/2009 |
Completion date | 20/09/2010 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | 30 |
Key inclusion criteria | 1. Subjects aged greater than or equal to 18 years, either sex 2. Multiple sclerosis (MS) according to the revised McDonald criteria 3. Relapsing-remitting form of MS 4. First-line disease modifying treatments (interferon-beta [IFN-beta] or glatiramer acetate) are contraindicated or not tolerated 5. Kurtzke's Expanded Disability Status Scale (EDSS) between 0 and 3.5 (0 to less than 3.5) 6. Subjects who experienced at least one relapse during the last 12 months or at least two relapses in the last 24 months prior to study entry 7. Freely given, fully informed written consent obtained from subject |
Key exclusion criteria | 1. Subjects who have received treatment with immunoglobulins for any reason previously 2. Subjects who have received immuno-suppressive treatments (e.g. azathioprine, mitoxantrone, cyclophosphamide) for any reason previously except relapse treatment with corticosteroids 3. Subjects who have received disease modifying first-line treatments with IFN-beta during the last 8 weeks or with glatiramer acetate during the last 16 weeks 4. Subjects who have received any monoclonal antibody therapies (e.g. natalizumab) previously 5. Subjects who had a relapse within 3 months prior to study entry 6. Subjects with severe renal function impairment as defined by serum creatinine values greater than 24 mg/l 7. Subjects with known intolerance to homologous immunoglobulins, especially immunoglobulin A (IgA) deficiency, when the subject has antibodies against IgA 8. Subjects with a body weight of greater than 120 kg 9. Subjects with a history of anaphylaxis after previous transfusions of blood or blood products 10. Subjects for whom magnetic resonance imaging (MRI) is contraindicated or who are allergic to gadolinium 11. Pregnant or lactating women 12. Subjects who delivered a baby within 12 months before study entry (including miscarriage and stillbirth) 13. Subjects with a diagnosis of significant depression 14. Subjects with known chronic infectious diseases or malignant disease 15. Subjects with known antibody deficiencies or other autoimmune diseases other than MS 16. Subjects participating in another study during the course of this study or during the past 6 months or who have ever participated in a study investigating in new disease modifying or immunosuppressive drugs |
Date of first enrolment | 20/03/2009 |
Date of final enrolment | 20/09/2010 |
Locations
Countries of recruitment
- Austria
- Germany
Study participating centre
Octapharma PPG
Vienna
1100
Austria
1100
Austria
Sponsor information
Octapharma AG (Switzerland)
Industry
Industry
Seidenstr. 2
Lachen
CH-8853
Switzerland
Website | http://www.octapharma.com |
---|---|
https://ror.org/002k5fe57 |
Funders
Funder type
Industry
Octapharma AG (Switzerland)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |